© 2019 MiCAN Technologies Inc.

KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan

​〒615-8245 京都市西京区御陵大原1-36 京大桂ベンチャープラザ

usa-icon.png
japan-icon.png

OUR PRODUCT

Progress of Drug R&D Highly Depends On the Supply of the Blood For Research

ABOUT OUR PRODUCT

Mpv

immature red blood-like cells for

Malaria (P.vivax) research

erythroid

progenitor cell

modified erythrocytic progenitor cell
for Malaria

red blood-like cell

suitable for

​Malaria research

Mpv cell kit

co-developed with Kyoto and Nagasaki Universities

M02

Mylc

special myeloid lineage cells for

Dengue and other infectious diseases

leukocyte

progenitor cell

modified myeloid

lineage cell
for Virus research

myeloid lineage cell

suitable for

​Dengue or Virus research

M02 cell kit

Mylc

co-developed with Universities

 start supplying products from 12th Dec, 2019

OUR PRODUCT VALUE

OUR TECHNOLOGY

Gene-Editing Technology

Our gene-editing technology can realize gene modifications of progenitor cells. (various gene-editing are possible upon request)

Our products have high level of uniformity, suitable for drug R&D

Differentiation- Induction Technology

Consistent- Production Technology

Providing sufficient amount of blood cells for evaluation inexpensively, after 3-year improvement of production efficiency.

IN THE PIPELINE

Final products will start to be shipped in the following year of releasing its pilot version.

We are planning to develop drugs and vaccines for infective diseases.

HIGH UNIFORMITY

 

Controlling differentiate stages of cells,

we achieved to produce

high uniformity of cells suitable

for precise drug developments.

RELIABLE SUPPLY

 

Produced with cutting edge technologies of regenerative medicine, high quality experimental cells are available at

anytime with sufficient amount.

LOW COST

 

Comparing to conventional human blood/ blood cells for experiments,
our products are far more affordable

in superior quality.

Our products are bottled
and securely packed, and delivered under the best possible condition.

ABOUT

​DELIVERY

Prompt Delivery

Next-day delivery from Kyoto, Japan to Bangkok, Thailand is possible*. In our trials, most of the cells delivered survived for several more days.

* A package of MPV cells departed our Kyoto lab at 13:20, arriving at Bangkok Airport at 13:15 the following day. The actual timing depends on traffic and flight conditions.

 

Why

​Needed?

Progress of Drug R&D Highly Depends On the Supply of the Blood For Research

Present issues regarding vivax malaria:

  • 8.5 million people affected every year

  • Suffering from drug resistance due to the use of generic drugs

Limited access to vivax malaria parasites;

  • Only grow in immature cells

  • Seasonal outbreak window of only two months

Tropical countries face the challenge of

combating many infectious diseases:

  • Ebola, Zika, Dengue, to name a few

  • W/W economic support from WHO/UN/private funds

  • Population reaching the threshold where they can afford medicine